|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 12, Num. 2, 2007, pp. 123-127
|
Comparing gonadotrophin-releasing hormone agonists or
gonadotrophin-releasing hormone antagonists in poor responder in IVF
Middle East Fertility Society Journal, Vol. 12, No. 2, 2007, pp. 123-127
Comparing
gonadotrophin-releasing hormone agonists or gonadotrophin-releasing hormone
antagonists in poor responder in IVF
Fatma Aletebi, F.R.C.S.
Department of Obstetrics
and Gynaecology, King Abdulaziz University, Jeddah, Saudi Arabia.
Correspondence: Department of Obstetrics and Gynaecology, King Abdulaziz University, PO Box 80215, Jeddah 21589, Saudi Arabia
Received on November 1, 2006; revised and accepted on January 15, 2007
Code Number: mf07021
ABSTRACT
Objective: The use of GnRH antagonist versus GnRH
agonist in poor responder for patient undergoing ovarian hyper-stimulation and in
vitro-fertilization was compared.
Materials
and Methods: In this
study, 23 patients underwent ovarian hyperstimulation with recombinant FSH
followed by the use of GnRH antagonist (Cetrorelix) 0.25mg during the late
Follicular Phase. These patients were compared to 20 patients who underwent
controlled ovarian hyper-stimulation with recombinant FSH proceeded by GnRH
agonist (short protocol).
Results: There was no significant difference
between the two groups for mean-age, duration of infertility or base line FSH,
number of ampoules of gonadotrophin used, number of mature oocyte retrieved, estradiol
concentration on the day of injection of human chronic gonadotrophin HCG,
fertilization rate and number of embryo transferred. The clinical pregnancy
rate in the antagonist group appear to be high but not significantly different
(12% compared to 10%).
Conclusion: The addition of GnRH antagonist to
ovarian stimulation protocol may be used for poor responder. Further randomized
clinical studies with large sample size required to elicit significant
differences.
Keywords: GnRH agonist, GnRH
antagonist, IVF, poor responders
Gonadotrophin-releasing
hormone agonists (GnRHa) and antagonists (GnRH-antag) have played an important
role in reducing the incidence of premature LH surges by blocking pituitary
gonadotrophin secretion. As a result, the rate of cancellation of assisted
conception cycles has decreased, and pregnancy rates increased (1,2). However,
each year many cycles are still cancelled due to poor ovarian response to
ovarian hyperstimulation.
Poor
responders are categorized as having a failure to respond to increasing doses
of gonadotrophins, sometimes administered to very high levels, when used in
conjunction with the analogue given.
Traditionally it was considered to be related to advanced maternal age, but it
also common today for some younger women, with normal day 3
follicle-stimulating hormone (FSH) values, to be difficult to stimulate. Overall,
nine to twenty-four percent of infertile women undergoing assisted reproduction
will have a poor response to ovarian stimulation (3).
In
this select category of patients, various strategies have been investigated in
an attempt to improve ovarian response, including the use of high doses of
gonadotrophins (4-6), the change to a flare-up protocol (7), and the use of
growth hormone or growth hormone-releasing factor (8,9), or aspirin (10) as
adjunct therapies. However, most of these interventions have met with only
limited success and the optimum stimulation protocol for poor responders is
still unclear.
Recently,
concern about the use of GnRH agonists in ovarian stimulation of poor
responders has arisen from the claim that GnRH agonists might have a direct
deleterious effect through their receptors on the ovary. Since
gonadotropin-releasing hormone agonists and antagonists work in using different
mechanisms, we wished to determine the beneficial effect of using a GnRH
antagonist compared with the flare-up or short GnRH agonist protocol in
patients that were considered to be poor responders to the standard long GnRH
agonist protocol.
MATERIALS AND METHODS
A
total of 43 poor-responder patients who underwent IVF-ET cycles were included. The
primary outcome measure was the clinical pregnancy rate. The secondary outcome
measures were gonadotropin needs for stimulation and ovarian response to
stimulation. This study was approved by the local ethical committee, and before
the treatment, informed consents were obtained from all patients.
Women
were eligible for inclusion if they had a baseline FSH levels of <15 mIU/mL
at previous IVF attempts. The definition of poor response was an unsuccessful
stimulation (no ovarian response when ≥300 IU of FSH are administered for ≥15 days) or low number
of oocytes retrieved (<5).
The
sample size of (144 participants) provides 80% power and a two-sided
significance level of 0.05 to test whether antagonist will be able to achieve
adequate number of oocytes (more than 3). This sample size has adequate power
to detect a difference of 5% between both protocols.
The
poor responders were randomly assigned into two groups according to the
analogue used. The first group consisted of 23 patients who underwent ovarian
hyperstimulation with recombinant FSH followed by the use of GnRH antagonist
(Cetrorelix) 0.25mg during the late Follicular Phase when follicle reach 15 mm.
The second group consisted of 20 patients who underwent controlled ovarian
hyper-stimulation with recombinant FSH proceeded by GnRH agonist (short
protocol).
In
each group, all patients initially received 450 IU of recombinant human FSH,
and the dose was adjusted individually according to the response of the ovaries. After 6 days of treatment with 450 IU/d, if no response was observed, the dose was
increased to 600 IU/d for 9 days. When response was obtained, the dose was
maintained until hCG administration. When at least one of the follicles reached
1618 mm in diameter, 10,000 U of hCG were administered IM.
Oocyte
retrieval was performed 36 hours after the hCG injection, and the embryos were
transferred on day 3 after oocyte collections. The cumulus-oocyte complex was
assessed according to the oocyte maturation score criteria. The oocytes were
then inseminated in vitro by conventional intracytoplasmic sperm injection, and
the resultant embryos were scored. After the transfer, all patients received a
Progesterone vaginal supplementation (micronized P, 400 mg/d) for two weeks.
Clinical pregnancy was defined as a positive BHCG at four weeks, and a visible
by ultrasound at 7 weeks gestation.
Statistical Analysis
Statistical
analysis was performed according to the intention to treat principle. The
results of the two groups were compared using the t-test or Mann-Whitney U test
for parametric and nonparametric data, respectively. Qualitative variables were
compared with the use of chi-square test with Yates correction or Fishers
exact test, when necessary, and Odds ratios (OR) and 95% confidence intervals
(95% CI) were calculated to examine the odds of improving clinical outcomes. Statistical
analysis was performed using Arcus Quickstat
RESULTS
There
was no significant difference between the two groups with regards the maternal
age, duration of infertility or baseline FSH (Table 1). In addition, there were no significant differences with regards
the number of ampoules of gonadotrophin used, number of mature oocyte
retrieved, estradiol concentration on the day of injection of human
Table 1. Patient and cycle
characteristics with pregnancy outcome
|
Group I
Antagonist
|
Group II
Short protocol
|
|
|
|
No. of patients |
23 |
20 |
Mean (±SD) age (years) |
39.15 ± 1.2 |
38.3 ± 1.3 |
Mean (±SD) duration of
infertility (years) |
13.55 ± 1.6 |
11.9 ± 1.2 |
No. of cycles |
23 |
20 |
Mean (±SD) FSH
concentration on cycle day 3 (mIU/ml) |
11. 49 ± 1.3 |
11.42 ± 1.2 |
Mean (±SD) LH
concentration on cycle day 3 |
6.32 ± 0.82 |
6.44 ± 0.76 |
No. of retrievals |
20 |
19 |
No. of transfers |
19 |
19 |
Mean (±SD) no. of rFSH ampoules
(100IU) |
60.8 ± 4.01 |
60.6 ± 4.02 |
Mean (±SD)
concentration of estradiol on the day of HCG administration |
850.46 ± 92.36 |
806.3 ± 85.51 |
Mean (±SD)
concentration of progesterone on the day of HCG administration |
0.7 ± 0.5 |
0.6 ± 0.4 |
Mean (±SD)
concentration of LH on the day of HCG administration |
7.72 ± 0.67 |
6.66 ± 0.65 |
Mean (±SD) no. of
mature oocyte retrieved |
3.54 ± 0.52 |
3.25 ± 0.25 |
Rate of metaphase
II/total oocytes (%) |
75.9 |
77.5 |
Fertilization rates (%) |
73.1 |
69.1 |
Mean (±SD) no. of
embryos transferred |
2.42 ± 0.32 |
2.29 ± 0.67 |
Clinical pregnancy/cycle (%) |
13 |
10 |
chorionic gonadotrophin
(HCG), fertilization rate and number of embryo transferred (Table 1). Even
though there was a higher clinical pregnancy rate in the antagonist group, but
this did reach statistical significance (13% compared to 10%).
DISCUSSION
Despite
the marked advances made in ovulation stimulation in the past twenty-years, the
ideal approach to poor ovarian responders is still highly debatable. The goal
of a stimulation protocol in these patients would be able to achieve optimum
oocyte retrieval, and at the same time, pregnancy rates.
Pituitary
down-regulation with GnRH agonists is characterized by an initial release of
FSH and LH during a short period (flare-up), followed by a subsequent
reduction of gonadotrophin release. In contrast, the pharmacological mechanism
by which GnRH antagonists suppress the release of gonadotrophins is completely
different.
In
general the agonists act on chronic administration through down-regulation of
receptors and desensitization of the gonadotrophic cells, while the antagonists
bind competitively to the receptors and thereby prevent the endogenous GnRH
from exerting its stimulatory effects on the pituitary cells. The GnRH
antagonists immediately and rapidly inhibit gonadotropin release by the
anterior pituitary gland by competitive blockage of the GnRH receptor,
preventing and interrupting luteinising hormone surges. The competitive
blockade of the receptors leads to an immediate arrest of gonadotrophin
secretion (11).
Recently,
it has been postulated that there may be a direct effect of GnRH agonists on
the ovary. This assumption is built on the fact that the ovary, like the
pituitary, has receptors to LHRH (12). This concept also hypothesizes that that
the human ovary may have its response to gonadotrophins suppressed to a
variable degree by the direct effect of GnRH analogues in certain patients. These
concerns about the use of GnRH agonists for poor responder patients, in which
there is a diminished ovarian reserve and therefore the use of GnRH agonists
might cause additional suppression, have encouraged clinicians to attempt other
protocols, including the use of the flare-up agonist and the antagonist
protocols.
Various
studies have attempted to determine which of these protocols is more efficient
and effective in patients with a history of being poor responders. Malmusi et
al performed a randomized controlled trial (RCT) in fifty-five poor-responder
patients in order to compare the efficacy of GnRH agonist flare-up and
GnRH-antagonist treatment protocols (13).
They noticed that the number of ampoules and units of FSH administered were
significantly less in the flare-up group, but the numbers of mature oocytes
retrieved and of top-quality embryos transferred were significantly greater in
the flare-up group. The fertilization rate (84% vs. 63%) was reported to be
significantly higher in the flare-up than in the GnRH-antagonist group. However
this did not affect the implantation and pregnancy rate were similar in the two
groups.
Recently a systematic review comparing the efficacy of
gonadotrophin antagonist (GnRH-ant) versus GnRH agonist (GnRHa) as coadjuvant
therapy for ovarian stimulation in poor ovarian responders in
IVF/intracytoplasmic sperm injection cycles was performed (14). The authors
concluded that there was a significantly higher number of retrieved oocytes (P
= 0.032; WMD: -0.51, 95% CI -0.99, -0.04) in the GnRHa protocols compare to the
antagonist protocol.
In our current study, 23 poor responders underwent
ovarian hyperstimulation with recombinant FSH followed by the use of GnRH
antagonist (Cetrorelix) 0.25mg during the late Follicular Phase. These patients
were compared to 20 patients who underwent controlled ovarian hyper-stimulation
with recombinant FSH proceeded by GnRH agonist (short protocol). The control
group was justified to be of short protocol as most of trials in the medical
literature compared antagonist to short protocol in normal responders.
This is the value of such study: to compare them in poor responders.
There was no significant difference between the two groups
for number of ampoules of gonadotrophin used, number of mature oocyte
retrieved, estradiol concentration on the day of injection of human chronic
gonadotrophin HCG, fertilization rate and number of embryo transferred. In
addition, there was no significant difference with regards the clinical
pregnancy rates (13% compared to 10%). The small number of participants can be
explained by the usual percent of poor responders within a certain period
of time in a single center like ours
CONCLUSIONS
The
use of GnRH agonist flare-up or antagonist protocols may be used for poor
responders. Further randomized clinical studies with large sample size are
required to confirm no significant differences in the outcome measures.
REFERENCES
- Albano
C, Smitz J, Camus M, Riethmuller-Winzen H, Siebert-Weiger M, Diedrich K, et al.
Hormonal profile during the follicular phase in cycles stimulated with a
combination of human menopausal gonadotrophin and gonadotrophin-releasing
hormone antagonist (Cetrorelix). Hum Reprod 1996;11(10):2114-2118.
- Hughes
EG, Fedorkow DM and Daya S. The routine use of gonadotropin releasing hormone
agonists prior to in-vitro fertilization and gamete intrafallopian transfer: a
meta-analysis of randomized controlled trials. Fertil Steril 1992;58, 888896.
- Keay
SD, Liversedge NH, Mathur RS and Jenkins JM. Assisted conception following poor
ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997;
104:521527.
- Hofmann
GE, Toner JP, Muasher SJ and Jones GS. High-dose
follicle stimulating hormone (FSH) ovarian stimulation in low responder
patients for in-vitro fertilization. J In Vitro Fertil Embryo Transf. 1993; 6,
285289.
- Karande
VC, Jones GS, Veeck LL and Muasher SJ. High-dose follicle-stimulating hormone
stimulation at the onset of the menstrual cycle does not improve the in vitro
fertilization outcome in low-responder patients. Fertil Steril. 1990; 53:
486489.
- Land
JA, Yarmolinskaya MI, Dumoulin JCM and Evers JLH. High-dose human menopausal
gonadotrophin stimulation in poor responders does not improve in vitro fertilization
outcome. Fertil Steril. 1996;65, 961965.
- Karande
V, Morris R, Rinehart J, Miller C, Rao R and Gleicher N. Limited success using
the flare protocol in poor responders in cycles with low basal follicle-stimulating
hormone levels during in vitro fertilization. Fertil Steril. 1997; 67:900903.
- Dor
J, Seidman DS, Amudai E, Bider D, Levran D and Mashiach S. Adjuvant growth
hormone therapy in poor responders to in-vitro fertilization: a prospective randomized
placebo-controlled double-blind study. Hum Reprod. 1995; 10:4043.
- Howles
CM, Loumaye E, Germond M, Yates R, Brinsden P, Healy D, Bonaventura LM and
Strowitzki T. Does growth hormone-releasing factor assist follicular
development in poor responder patients undergoing ovarian stimulation for
in-vitro fertilization? Hum Reprod. 1999; 14, 19391943.
- Lok
IH, Yip SK, Cheung LP, Leung PHY and Haines CJ. Adjuvant low-dose aspirin
therapy in poor responders undergoing in vitro fertilization: a prospective, randomized,
double-blind, placebo-controlled trial. Fertil Steril. 2004; 81:556561.
- Felberbaum
RE, Reissmann T, Kuper W, Bauer O, al Hasani S, Diedrich C, et al. Preserved
pituitary response under ovarian stimulation with hMG and GnRH-antagonists
(Cetrorelix) in women with tubal infertility. European Journal of Obstetrics,
Gynecology and Reproductive Biology 1995;61(2):151-155.
- Leung,
P.C.K. GnRH receptor and potential action in human ovary. Gynaecol. Endocrinol.
1999; 13, 10.
- Malmusi
S. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH
agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril. 2005
Aug;84(2):402-6.
- Franco
JG Jr, Baruffi RLR, Mauri AL, Petersen CG, Felipe V, Cornicelli J, Cavanga M,
Oliveira JBA. GnRH
agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis. RBM
Online. 2006 Nov;13(5): 618627.
Copyright © Middle East Fertility Society
|